Krakow, Poland – May 14, 2021 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that dr Krzysztof Brzozka, Chief Scientific Officer at Ryvu Therapeutics will give a presentation “New generation of STING agonists – development and characterization of a novel series of systemic immunomodulators with improved potency” during The 2nd STING- & TLR-Targeting Therapies Summit, on May 26, 2021.
The conference is dedicated to the topic of the development of drug candidates modulating the cGAS-STING pathway and Toll-like receptor signaling both as monotherapies and as adjuvants in combinatorial approaches, and will be held virtually on May 25-27, 2021.
Dr. Brzozka will hold his presentation on May 26, at 2:25 PM (EST)/11:25 AM (PST), and the scope of his talk will include:
- Results of a new generation Ryvu STING agonists which are strong binders of human STING protein and show high cellular potency of inducing cytokine production in human immune cells at low nM range;
- The profile of compounds which are characterized by drug-like properties and high in vitro potency irrespective of the natural human STING variant and the chemotype is amenable for linking technologies allowing targeted delivery
- Data presenting high cellular potency of Ryvu series which translates into efficacy observed in vivo, where systemic intravenous administration leads to complete tumor regressions in mouse syngeneic models
To register for the conference or find out more information about this event please visit: https://sting-tlr-targeting-therapies.com/